Episode Details
Back to Episodes
Pharmaceutical Executive Daily: FDA Expands Approvals for Tzield and Dupixent
Published 3 weeks, 6 days ago
Description
In today’s Pharmaceutical Executive Daily, the FDA expands the use of Tzield to young children to delay the onset of stage 3 type 1 diabetes, Dupixent receives an expanded pediatric indication in chronic spontaneous urticaria, and AbbVie announces a $195 million investment to build a new manufacturing campus in North Carolina.